Rib-X Inks Research Agreement With Sanofi
New Haven, CT-based Rib-X Pharmaceuticals announced today that it could receive about $772 million from Sanofi (NYSE: SNY) under a new research collaboration and option for Sanofi to license novel classes of antibiotics from Rib-X’s RX-04 program for the treatment of resistant Gram-negative and resistant Gram-positive infections. Sanofi paid $10 million upfront and could pay up to $9 million in near-term research milestones, as well as other clinical and commercialization milestones and royalties. Rib-X could also receive $86 million in development and regulatory milestones and $100 million in commercial milestones for each product identified in the collaboration—Sanofi is targeting four for now, but there is no upper limit, the companies said.
Trending on Xconomy
By posting a comment, you agree to our terms and conditions.